I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

ADPD 2023

-
Coming soon
08:00 AM
Duration 15mins Gothenburg, Sweden / hybrid (virtual)
A Phase 1b Study to Test the Safety, Pharmacokinetics, and Pharmacodynamics of Selnoflast, a Novel NLRP3 Inflammasome Inhibitor, in Early Stage Parkinson’s Disease: Rationale and Study Design
Gennaro Pagano, Giulia D’Urso, Alessandra E. Thomann, Judith Anzures Cabrera, Bastian Zinnhardt, Benedicte Ricci, Lorna Bailey, Krzysztof Smigorski, Venissa Machado, Eva Zsuzsanna Mracsko, Nicola Pavese, Kenneth Marek, Kathrin Brockmann, Tanya Simuni, Nicoletta, Milani Muelhardt
07:00 AM
Duration 15mins On demand Gallery E
THE ABOUT ME CARE CARD: AN SHARED DECISION-MAKING (SDM)-BASED TOOL TO PROMOTE PURPOSEFUL DEMENTIA CARE
Mr Greg Kotzbauer, Dr Mikele Epperly, Ms Yee Huey Tan, Ms Supriya Yagnik, Dr Heather Kang, and Prof. Stuart Grande
03:20 PM
Duration 15mins HALL F1+F2+F3
GRADUATE I AND II: EFFICACY RESULTS FROM TWO PHASE III TRIALS OF SUBCUTANEOUS GANTENERUMAB IN EARLY ALZHEIMER’S DISEASE
Bateman R, Smith J, Donohue M, Delmar P, Gruendl E, Boada M, Rutten-Jacobs L, Lane C, Cummings J, Fontoura P, Doody RS
03:35 PM
Duration 15mins HALL F1+F2+F3
GRADUATE I AND II: SAFETY RESULTS FROM TWO PHASE III TRIALS OF SUBCUTANEOUS GANTENERUMAB IN EARLY ALZHEIMER’S DISEASE
Salloway S, Lyons M, Lane C, Rossomanno S, Wojtowicz J, Plank R, Warren F, Smith J, Boada M, Doody RS
02:50 PM
Duration 15mins HALL F1+F2+F3
ALUMNI AD STUDY DESIGN:Evaluation of Subcutaneous Gantenerumab in Historically Underrepresented US Populations With Early Symptomatic Alzheimer’s Disease
Seleri Assuncao S, Brangman S, Henderson J, Parker M, Monroe S, Mintzer J, Wise-Brown A, Grundman M, Smith J, Doody R, Lin H, Assman B, Rippon G
03:05 PM
Duration 15mins HALL F1+F2+F3
GRADUATE I AND II RESULTS: EFFECT OF SUBCUTANEOUS GANTENERUMAB ON FLUID BIOMARKERS OF AD PATHOLOGY AND NEURODEGENERATION
Bittner T, Blennow K, Scelsi M, Palermo G, Kollmorgen G, Smith J, Zetterberg H, Doody RS
03:20 PM
Duration 15mins HALL F1+F2+F3
GRADUATE I AND II: IMAGING FINDINGS FROM TWO PHASE III TRIALS OF SUBCUTANEOUS GANTENERUMAB IN EARLY ALZHEIMER’S DISEASE
Barkhof F, Klein G, Tonietto M, Bittner T, Ahlers S, Abbas R, MD, Smith J, Fox N, Black S, Hansson O, Doody RS
07:10 PM
Duration 15mins ONSITE - HALL G4
ATTITUDES OF NEUROLOGISTS TOWARDS THE USE OF BIOMARKERS IN THE DIAGNOSIS OF EARLY-STAGE ALZHEIMER'S DISEASE
Elena Garcia Arcelay, Luisa Guglielmini, Marie Bordone, Alonso Montoya, Jorge Maurino, Guillermo Garcia-Ribas